Abstract
Background:
Ocular melanoma (OM) metastasizes to the liver and is rapidly fatal despite aggressive therapy. Yttrium-90 microspheres (radioembolization) delivered via the hepatic artery is an established and effective approach for primary and metastatic hepatic tumors, although (90)Y use in OM has not been reported previously.
Methods:
A retrospective review was performed for all patients with OM who received radioembolization at 5 centers.
Results:
11 patients received 12 treatments with a median activity of 1.55 GBq delivered per treatment. Toxicity was minimal, with PET/CT at 3 months posttreatment showing a response in all patients; 1 patient had a complete response.
Conclusions:
Radioembolization can control hepatic metastases of OM with very few side effects.
MeSH terms
-
Adult
-
Aged
-
Angiography, Digital Subtraction
-
Brachytherapy* / adverse effects
-
Embolization, Therapeutic* / adverse effects
-
Europe
-
Eye Neoplasms / pathology*
-
Female
-
Hepatic Artery
-
Humans
-
Injections, Intra-Articular
-
Israel
-
Kaplan-Meier Estimate
-
Liver Neoplasms / mortality
-
Liver Neoplasms / radiotherapy*
-
Liver Neoplasms / secondary
-
Magnetic Resonance Imaging
-
Male
-
Melanoma / mortality
-
Melanoma / radiotherapy*
-
Melanoma / secondary
-
Microspheres
-
Middle Aged
-
Positron-Emission Tomography
-
Radiopharmaceuticals / administration & dosage
-
Radiopharmaceuticals / adverse effects
-
Radiopharmaceuticals / therapeutic use*
-
Retrospective Studies
-
Time Factors
-
Tomography, X-Ray Computed
-
Treatment Outcome
-
United States
-
Yttrium Radioisotopes / administration & dosage
-
Yttrium Radioisotopes / adverse effects
-
Yttrium Radioisotopes / therapeutic use*
Substances
-
Radiopharmaceuticals
-
Yttrium Radioisotopes